表紙
市場調查報告書

組蛋白甲基轉移酶變異體 EZH2:開發中產品分析

Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 371024
出版日期 內容資訊 英文 96 Pages
訂單完成後即時交付
價格
Back to Top
組蛋白甲基轉移酶變異體 EZH2:開發中產品分析 Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 96 Pages
簡介

本報告提供以組蛋白甲基轉移酶變異體為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊EZH2。

簡介

  • 調查範圍

組蛋白甲基轉移酶變異體 EZH2 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Constellation Pharmaceuticals, Inc.
  • 第一三共
  • Domainex Limited
  • EpiZyme, Inc.
  • GlaxoSmithKline Plc
  • Kainos Medicine, Inc.
  • Pfizer Inc.
  • Transgene Biotek Limited
  • UNC Health Care

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2197TDB

Summary

According to the recently published report 'Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019'; Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme encoded by EZH2 gene. EZH2 methylates non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. It regulates the circadian clock via histone methylation at the promoter of the circadian genes. It is essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer, involved in the di and trimethylation of Lys-27 of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription.

The report 'Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019' outlays comprehensive information on the Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 6 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology and Undisclosed which include indications Diffuse Large B-Cell Lymphoma, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Follicular Lymphoma, Multiple Myeloma (Kahler Disease), Small-Cell Lung Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bladder Cancer, Breast Cancer, Central Nervous System (CNS) Tumor, Chondrosarcoma, Chordoma, Endometrial Cancer, Epithelial Tumor, Glioblastoma Multiforme (GBM), Hematological Tumor, Hepatocellular Carcinoma, Leukemia, Lung Cancer, Malignant Mesothelioma, Melanoma, Metastatic Liver Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Neuroblastoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Tumor, Squamous Non-Small Cell Lung Cancer, Synovial Sarcoma, T-Cell Leukemia, T-Cell Lymphomas, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC), Unspecified, Uterine Cancer and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43)
  • The report reviews Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Overview
  • Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Companies Involved in Therapeutics Development
  • Constellation Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Domainex Ltd
  • Epizyme Inc
  • Eternity Bioscience Inc
  • GlaxoSmithKline Plc
  • Ionis Pharmaceuticals Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Kainos Medicine Inc
  • OncoFusion Therapeutics Inc
  • Pfizer Inc
  • Transgene Biotek Ltd
  • Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Drug Profiles
  • CPI-0209 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CPI-1205 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CPI-169 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EBI-2554 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GSK-343 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IONISEZH-22.5Rx - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JQEZ-5 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KM-301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MS-1943 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ORS-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-06821497 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SHR-2554 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit EZH1 and EZH2 for Leukemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit EZH2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit EZH2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit EZH2-EED for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tazemetostat hydrobromide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TBL-0404 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • valemetostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Dormant Products
  • Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Discontinued Products
  • Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 18, 2019: Epizyme submits new drug application to the U.S. FDA for Tazemetostat for the treatment of patients with follicular lymphoma
  • Dec 18, 2019: Epizyme (EPZM) trading of stock halted; Oncology drug advisory committee to review Tazemetostat
  • Dec 18, 2019: Epizyme announces FDA Advisory Committee votes unanimously in favor of Tazemetostat for the treatment of patients with epithelioid sarcoma
  • Dec 11, 2019: Daiichi Sankyo initiates Phase II study of valemetostat to treat ATL
  • Dec 09, 2019: Researchers create a potential therapy for deadly Breast Cancer that has few treatment options
  • Dec 07, 2019: Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
  • Dec 02, 2019: Epizyme announces FDA Advisory Committee Meeting to review Tazemetostat for the treatment of patients with epithelioid sarcoma
  • Nov 06, 2019: Daiichi Sankyo showcases data presentations on valemetostat at American Society of Hematology (ASH)
  • Oct 30, 2019: Epizyme announces positive pre-NDA meeting for Tazemetostat for Follicular Lymphoma
  • Sep 24, 2019: Constellation Pharmaceuticals advances CPI-0209 into Clinical Trials, expanding its EZH2 franchise
  • Jul 25, 2019: Epizyme announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma
  • Jun 24, 2019: Epizyme reports positive data from trial of FL therapy tazemetostat
  • Jun 12, 2019: Epizyme announces conference call to discuss phase 2 Tazemetostat follicular lymphoma data
  • Jun 12, 2019: Constellation Pharmaceuticals presentation highlights enhanced EZH2 target engagement, leading to second-generation EZH2 inhibitor CPI-0209
  • Jun 03, 2019: Epizyme reports updated data from Phase 2 trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Constellation Pharmaceuticals Inc, H2 2019
  • Pipeline by Daiichi Sankyo Co Ltd, H2 2019
  • Pipeline by Domainex Ltd, H2 2019
  • Pipeline by Epizyme Inc, H2 2019
  • Pipeline by Eternity Bioscience Inc, H2 2019
  • Pipeline by GlaxoSmithKline Plc, H2 2019
  • Pipeline by Ionis Pharmaceuticals Inc, H2 2019
  • Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
  • Pipeline by Kainos Medicine Inc, H2 2019
  • Pipeline by OncoFusion Therapeutics Inc, H2 2019
  • Pipeline by Pfizer Inc, H2 2019
  • Pipeline by Transgene Biotek Ltd, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top